Progestagens use before menopause and breast cancer risk according to histology and hormone receptors

Alban Fabre, Agnès Fournier, Sylvie Mesrine, Anne Gompe, Joëlle Desreux, Franco Berrino, Marie Christine Boutron-Ruault, Isabelle Romieu, Françoise Clavel-Chapelon

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for

Original languageEnglish
Pages (from-to)2723-2728
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Progestins
Menopause
Histology
Hormones
Breast Neoplasms
Confidence Intervals
Lobular Carcinoma
Progesterone Receptors
Proportional Hazards Models
Estrogen Receptors
Cohort Studies
Carcinoma

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Fabre, A., Fournier, A., Mesrine, S., Gompe, A., Desreux, J., Berrino, F., ... Clavel-Chapelon, F. (2008). Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. Cancer Epidemiology Biomarkers and Prevention, 17(10), 2723-2728. https://doi.org/10.1158/1055-9965.EPI-08-0056

Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. / Fabre, Alban; Fournier, Agnès; Mesrine, Sylvie; Gompe, Anne; Desreux, Joëlle; Berrino, Franco; Boutron-Ruault, Marie Christine; Romieu, Isabelle; Clavel-Chapelon, Françoise.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 10, 10.2008, p. 2723-2728.

Research output: Contribution to journalArticle

Fabre, A, Fournier, A, Mesrine, S, Gompe, A, Desreux, J, Berrino, F, Boutron-Ruault, MC, Romieu, I & Clavel-Chapelon, F 2008, 'Progestagens use before menopause and breast cancer risk according to histology and hormone receptors', Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 10, pp. 2723-2728. https://doi.org/10.1158/1055-9965.EPI-08-0056
Fabre, Alban ; Fournier, Agnès ; Mesrine, Sylvie ; Gompe, Anne ; Desreux, Joëlle ; Berrino, Franco ; Boutron-Ruault, Marie Christine ; Romieu, Isabelle ; Clavel-Chapelon, Françoise. / Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 10. pp. 2723-2728.
@article{d6819e6b86f24aeb9d390b978fa7ab33,
title = "Progestagens use before menopause and breast cancer risk according to histology and hormone receptors",
abstract = "In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95{\%} confidence interval (95{\%} CI), 1.02-2.24 and HR, 1.38; 95{\%} CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95{\%} CI, 1.05-2.68), whereas current use of progestagens for",
author = "Alban Fabre and Agn{\`e}s Fournier and Sylvie Mesrine and Anne Gompe and Jo{\"e}lle Desreux and Franco Berrino and Boutron-Ruault, {Marie Christine} and Isabelle Romieu and Fran{\cc}oise Clavel-Chapelon",
year = "2008",
month = "10",
doi = "10.1158/1055-9965.EPI-08-0056",
language = "English",
volume = "17",
pages = "2723--2728",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Progestagens use before menopause and breast cancer risk according to histology and hormone receptors

AU - Fabre, Alban

AU - Fournier, Agnès

AU - Mesrine, Sylvie

AU - Gompe, Anne

AU - Desreux, Joëlle

AU - Berrino, Franco

AU - Boutron-Ruault, Marie Christine

AU - Romieu, Isabelle

AU - Clavel-Chapelon, Françoise

PY - 2008/10

Y1 - 2008/10

N2 - In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for

AB - In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for

UR - http://www.scopus.com/inward/record.url?scp=54249091768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249091768&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0056

DO - 10.1158/1055-9965.EPI-08-0056

M3 - Article

VL - 17

SP - 2723

EP - 2728

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -